

# Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome\*

Helena J. Teede,<sup>1,2</sup> Chau Thien Tay,<sup>1,2</sup> Joop J. E. Laven,<sup>2,3</sup> Anuja Dokras,<sup>4</sup> Lisa J. Moran,<sup>1,2</sup> Terhi T. Piltonen,<sup>5</sup> Michael F. Costello,<sup>2,6</sup> Jacky Boivin,<sup>7</sup> Leanne M. Redman,<sup>8</sup> Jacqueline A. Boyle,<sup>2,9</sup> Robert J. Norman,<sup>2,10</sup> Aya Mousa,<sup>1</sup> and Anju E. Joham,<sup>1,2</sup> on behalf of the International PCOS Network<sup>†</sup>

<sup>1</sup>Monash Centre for Health Research and Implementation, Monash University and Monash Health, Melbourne, Victoria, Australia

<sup>2</sup>National Health and Medical Research Council Centre for Research Excellence in Women's Health in Reproductive Life, Melbourne, Victoria, Australia

<sup>3</sup>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Rotterdam, The Netherlands

<sup>4</sup>Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

<sup>5</sup>Department of Obstetrics and Gynaecology, Medical Research Center Oulu, Research Unit of Clinical Medicine, University of Oulu and Oulu University Hospital, Oulu, Finland

<sup>6</sup>University of New South Wales, New South Wales, Australia

<sup>7</sup>Cymru Fertility and Reproductive Research, School of Psychology, Cardiff University, Cardiff, Wales, UK

<sup>8</sup>Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA

<sup>9</sup>Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia

<sup>10</sup>Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia

**Correspondence:** Helena J. Teede, PhD, Monash University and Monash Health, Locked Bag 29, Clayton, Australia, 3168, VIC, Australia.

Email: [helena.teede@monash.edu](mailto:helena.teede@monash.edu).

\*This article is simultaneously published in *Fertility and Sterility*, *Journal of Clinical Endocrinology and Metabolism*, *European Journal of Endocrinology* and *Human Reproduction*.

<sup>†</sup>Participants of the International PCOS Network are listed in the Appendix.

## Abstract

**Study Question:** What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference?

**Summary Answer:** International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS.

**What is Known Already:** The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from six continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low to low quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, evidence quality was low and evidence-practice gaps persist.

**Study Design, Size, Duration:** The 2023 International Evidence-based Guideline update reengaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength and diversity and inclusion were considered throughout.

**Participants/Materials, Setting, Methods:** This summary should be read in conjunction with the full Guideline for detailed participants and methods. Governance included a six-continent international advisory and management committee, five guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health and other experts, alongside consumers, project management, evidence synthesis, statisticians and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and five face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across five guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council (NHMRC).

Received: 2 August 2023. Editorial Decision: 2 August 2023. Corrected and Typeset: 15 August 2023

This article has been co-published with permission in The Journal of Clinical Endocrinology and Metabolism, Human Reproduction, European Journal of Endocrinology, and Fertility and Sterility. © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style.

**Main Results and the Role of Chance:** The evidence in the assessment and management of PCOS has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report and analyses (~6000 pages) underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include: i) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only; ii) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; iii) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making to improve patient experience, alongside greater research; iv) maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and v) emphasizing evidence-based medical therapy and cheaper and safer fertility management.

**Limitations, Reasons for Caution:** Overall, recommendations are strengthened and evidence is improved, but remain generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided.

**Wider Implications of the Findings:** The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation programme supports the Guideline with an integrated evaluation program.

**Study Funding/Competing Interest(s):** This effort was primarily funded by the Australian Government via the National Health Medical Research Council (NHMRC) (APP1171592), supported by a partnership with American Society for Reproductive Medicine, Endocrine Society, European Society for Human Reproduction and Embryology, and the European Society for Endocrinology. The Commonwealth Government of Australia also supported Guideline translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships. JT is funded by a Royal Australasian College of Physicians (RACP) fellowship. Guideline development group members were volunteers. Travel expenses were covered by the sponsoring organizations. Disclosures of interest were strictly managed according to NHMRC policy and are available with the full guideline, technical evidence report, peer review and responses ([www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittel GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim. The guideline was peer reviewed by special interest groups across our 39 partner and collaborating organizations, was independently methodologically assessed against AGREEII criteria and was approved by all members of the guideline development groups and by the NHMRC.

**Key Words:** polycystic ovary syndrome, guideline, evidence-based, assessment, management, GRADE

## What Does This Mean for Those With PCOS?

Building on the 2018 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (PCOS), this Guideline updates and expands clinical questions, aiming to ensure that women with PCOS receive optimal, evidence-based care that meets their needs and improves health outcomes. The guideline and translation program were developed with full consumer participation at all stages including priority topics and outcomes for those with PCOS. The aim is to support women and their healthcare providers to optimize diagnosis, assessment and management of PCOS. There is an emphasis on improved education and awareness of healthcare professionals, partnership in care, and empowerment of women with PCOS. Personal characteristics, preferences, culture and values are considered, in addition to resource availability across different settings. With effective translation, the Guideline will address priorities identified by women with PCOS, upskill healthcare professionals, empower consumers, improve care and outcomes, identify key research gaps, and promote vital future research.

## Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive-aged women, with impacts across the lifespan from adolescence to post menopause. PCOS prevalence is between 10% to 13% as confirmed in the guideline process (1, 2). PCOS aetiology is complex; clinical presentation is heterogeneous with reproductive, metabolic, and psychological features (1, 2). Women internationally

experience delayed diagnosis and dissatisfaction with care (3-5). Clinical practice in the assessment and management of PCOS remains inconsistent, with ongoing key evidence-practice gaps. Following on from the 2018 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (6, 7), independently evaluated as high quality, this extensive update integrates current literature with previous systematic reviews and extends to new clinical questions prioritized by consumers. Ultimately, we aim to update, extend and translate rigorous, comprehensive evidence-based guidelines for diagnosis, assessment and treatment, to improve the lives of those with PCOS worldwide.

To do so, the Guideline leverages substantive government and society investment and brings together extensive consumer engagement and international collaboration with leading societies and organizations, multidisciplinary experts, and primary care representatives. This comprehensive evidence-based Guideline is constructed from a rigorous, Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant, evidence-based guideline development process. It provides a single source of international evidence-based recommendations to guide clinical practice with the opportunity for adaptation in relevant health systems. Together with an extensive translation program, the aim is to reduce worldwide variation in care and promote high quality clinical service provision to improve health outcomes and quality of life in women with PCOS. The Guideline is supported by a multifaceted international translation programme with co-designed resources to enhance the skills of healthcare professionals and to empower women with PCOS, with an integrated comprehensive evaluation program. Here, we summarize recommendations from the

**Table 1. Categories of PCOS guideline recommendations**

EBR	Evidence Based Recommendations: Evidence sufficient to inform a recommendation made by the guideline development group.
CR	Consensus Recommendations: In the absence of adequate evidence, a consensus recommendation has been made by the guideline development group, also informed by evidence from the general population.
PP	Practice Points: Evidence not sought. A practice point has been made by the guideline development group where important issues arose from discussion of evidence-based or consensus recommendations.

Abbreviation: PCOS, polycystic ovary syndrome.

2023 International Evidence-based Guideline for the Assessment and Management of PCOS.

**Materials and Methods**

Best practice evidence-based guideline development methods were applied and are detailed in the full Guideline and the technical report, which are available online ([www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)) (8). In brief, extensive healthcare professional and consumer or patient engagement informed the Guideline priority areas. International society-nominated panels from across three leading entities, four partner organizations and thirty-two collaborating entities included consumers and experts in paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, psychology, dietetics, exercise physiology, sleep, bariatric/metabolic surgery, public health, other co-opted experts, project management, evidence synthesis and translation. Governance included an international advisory and a management committee, five guideline development groups (GDGs) with 56 members, and paediatric, consumer, and translation committees. The five GDGs covered i) Screening, diagnostic and risk assessment and life stage; ii) Psychological features and models of care; iii) Lifestyle management; iv) Management of nonfertility features; and v) Assessment and management of infertility. The leading entities; the Australian National Health and Medical Research Council (NHMRC) Centres for Research Excellence in Women’s Health in Reproductive Life and in Polycystic Ovary Syndrome, led by Monash University, partnered with the American Society for Reproductive Medicine, the Endocrine Society, the European Society of Endocrinology and the European Society of Human Reproduction and Embryology and collaborated with 32 other entities. With international meetings over 12 months fifty-five prioritized clinical questions involved 52 systematic and three narrative reviews, generating evidence-based and consensus recommendations with accompanying practice points. Committee members nominated by partner and collaborator organizations provided international peer review, and independent experts reviewed methods which were then submitted to NHMRC for independent review. The target audience includes multidisciplinary healthcare professionals, consumers or patients, policy makers, and educators. The Guideline includes a focus on equity, cultural and ethnic diversity, avoidance of stigma and inclusivity (see full guideline for details).

Processes aligned with all elements of the AGREE-II tool for quality guideline assessment (9), with extensive evidence

**Table 2. Quality (certainty) of evidence categories (adapted from GRADE)**

High	⊕⊕⊕⊕	Very confident that the true effect lies close to that of the estimate of the effect.
Moderate	⊕⊕⊕○	Moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is different.
Low	⊕⊕○○	Limited confidence in the effect estimate. The true effect may be substantially different from the estimate of the effect.
Very Low	⊕○○○	Very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.

Abbreviation: GRADE, Grading of Recommendations, Assessment, Development, and Evaluation.

synthesis and meta-analysis. Integrity assessment was integrated into guideline evidence synthesis processes and followed the Research Integrity in Guideline Development (RIGID) framework, with studies assessed against criteria from the Research Integrity Assessment (RIA) tool and the Trustworthiness in RANdomised Controlled Trials (TRACT) checklist (10-12). Evidence synthesis methods are outlined in the full guideline and followed best practice (9, 13, 14) Guideline recommendations are presented by category, terms used, evidence quality and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework considerations. Category includes evidence-based (sufficient evidence in PCOS) or consensus (insufficient evidence in PCOS, also evidence in general or relevant populations was considered) recommendations and accompanying practice points (implementation considerations) (Table 1).

The terms include “should”, “could” and “should not”, which are informed by the nature of the recommendation (evidence or consensus), the GRADE framework and the evidence quality and are independent descriptors reflecting GDG judgement. They refer to overall interpretation and practical application of the recommendation, balancing benefits and harms. “Should” is used where benefits of the recommendation exceed harms and where the recommendation can be trusted to guide practice. Conditional recommendations are reflected using the terms “could” or “should/could consider” which are used where evidence quality was limited or available studies demonstrate little clear advantage of one approach over another, or the balance of benefits to harms was unclear. “Should not” applies when there is a lack of appropriate evidence, or harms may outweigh benefits.

Evidence quality was categorized according to the GRADE framework, with judgments about the quality of the included studies and/or synthesized evidence incorporating risk of bias, inconsistency, indirectness, imprecision and any other considerations (eg, publication bias) that may influence evidence quality. These judgments considered study number and design, statistical data and importance of outcomes (Table 2). The quality of evidence reflects the confidence that the estimate of the effect is adequate to support each recommendation (13), largely determined by the expert evidence synthesis team. GRADE acknowledges that evidence quality is a continuum; any discrete categorization involves some arbitrary decisions; nevertheless, the advantages of

**Table 3. The grading of recommendations, assessment, development, and evaluation (GRADE) framework recommendation strength**

❖	Conditional recommendation against the option.
❖❖	Conditional recommendation for either the option or the comparison.
❖❖❖	Conditional recommendation for the option.
❖❖❖❖	Strong recommendation for the option.

simplicity, transparency, and clarity outweigh these limitations (13).

The GRADE framework enabled structured and transparent consideration across evidence quality, feasibility, acceptability, cost, implementation, and ultimately recommendation strength (13) and was completed at face to face guideline group meetings for all clinical questions (Table 3) (15).

Notably, certainty of evidence varied across outcomes within each question. Here evidence certainty reflects the lowest certainty for the critical outcomes. Evidence was often stronger for the top ranked outcome, and high quality randomized controlled trials (RCTs) were often present, despite overall low quality of evidence. These nuances were considered by the GDG for all question as per the technical report, with any apparent discrepancy between recommendation strength and evidence certainty justified in the full Guideline. Finally, we note that this is a living Guideline with annual evidence review in rapidly evolving areas.

The recommendations (Table 4) apply the category, descriptive terms, GRADE of the recommendations and the quality of the evidence. The full Guideline, technical evidence and administrative reports are available online ([www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)). The Guideline outlines the clinical need for the question, the clinical question, the evidence summary, the recommendations and practice points, and a summary of the justification developed by the GDGs using the GRADE framework. Extensive international peer review from across the 39 organizations was then considered by each GDG and recommendations were reconsidered applying the GRADE framework if justified. The comprehensive evidence reviews, profiles, and GRADE frameworks supporting each recommendation can be found in the Technical Report. The administrative report on guideline development, disclosure of interest process and declarations, peer review feedback and responses can also be found online. Here, we present the evidence-based and consensus recommendations and practice points (Table 4). This summary, the full Guideline and technical reports are supported by a comprehensive co-designed translation program to optimize dissemination and impact with resources freely available online ([www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)).

Two algorithms are provided to support recommendations on diagnosis (Fig. 1) and infertility management (Fig. 2).

## Discussion

The International Evidence-based Guideline for the Assessment and Management of PCOS and the related translation program aims to provide a high quality, reliable source of international evidence-based recommendations to guide consistent clinical practice and to empower women with evidence-based information. All recommendations were formulated after an assessment of the best available evidence,

multidisciplinary clinical expertise, consumer preferences and structured review by five GDGs. The guideline provides 77 evidence-based and 54 consensus recommendations, with 123 practice points underpinned by a technical report on evidence synthesis and GRADE detailed considerations (~6000 pages). The evidence has generally improved over the past five years but remains of low to moderate quality, requiring significant research investment into this neglected, yet common condition.

Key recommendations and updates include that PCOS should be diagnosed using the 2018 International Evidence-based Guideline criteria, which built on the consensus based 2003 Rotterdam criteria. This requires the presence of two of the following: i) clinical/biochemical hyperandrogenism; ii) ovulatory dysfunction; and iii) polycystic ovaries on ultrasound; and here in 2023, alternatively anti-Müllerian hormone (AMH) can now be used instead of ultrasound. Exclusion of other aetiologies. Importantly, where irregular menstrual cycles and hyperandrogenism are present, diagnosis is simplified and ultrasound or AMH are not required for diagnosis. In adolescents, both hyperandrogenism and ovulatory dysfunction are required, with ultrasound and AMH not recommended due to poor specificity. AMH was highlighted as a rapidly evolving area in 2018 and evidence is now strong enough to make this new recommendation. This will significantly change practice and offers women a low cost, convenient option, without evidence of overdiagnosis.

Insulin resistance is recognized as a key feature of PCOS, yet routinely available measures of insulin resistance are inaccurate and clinical measurement is not currently recommended. Once diagnosed, assessment and management should address reproductive, metabolic, cardiovascular, dermatologic, sleep, and psychological features. A lifelong health plan is recommended including a focus on healthy lifestyle, prevention of excess weight gain, optimization of fertility and preconception risk factors, and prevention and treatment of diverse clinical features. These include metabolic risk factors, diabetes, cardiovascular disease, and sleep disorders, which are all increased in PCOS. PCOS should be considered a high-risk condition in pregnancy with women identified and monitored. An increased premenopausal risk of endometrial cancer should also be recognized, whilst absolute risks remain low.

Symptoms of depression and anxiety are significantly increased and should be screened for in all women with PCOS, with psychological assessment and therapy as indicated. Greater awareness of psychological features including eating disorders and impacts on body image and quality of life is needed.

Dissatisfaction with PCOS diagnosis and care is high and significant improvement in education and awareness is strongly recommended for women and healthcare professionals including high quality, evidence-based resources. Shared decision making and self-empowerment are fundamental and integrated models of care should be codesigned, funded and evaluated.

Supported healthy lifestyle remains vital throughout the lifespan in PCOS, with a strong focus on overall health, prevention of weight gain and, if required, on weight management. Recognizing the benefits of many diet and physical activity regimens, there is no one specific regimen that has benefits over others in PCOS. Weight bias and stigma should be minimized and healthcare professionals should seek permission to weigh women, with explanation of weight-related risks.



**Table 4. Recommendations for the assessment and management of polycystic ovary syndrome (PCOS).** © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023.

No.	Type	Recommendation	Grade/quality
<b>1</b>		<b>Screening, diagnostic and risk assessment, and life stages</b>	
		General principles	
	PP	All diagnostic assessments are recommended for use in accordance with the diagnostic algorithm (Algorithm 1).	
<b>1.1</b>		<b>Irregular cycles and ovulatory dysfunction</b>	
1.1.1	CR	Irregular menstrual cycles are defined as follows: <ul style="list-style-type: none"> <li>• Normal in the first year post menarche as part of the pubertal transition.</li> <li>• 1 to &lt;3 years post menarche: &lt;21 or &gt;45 days.</li> <li>• 3 years post menarche to perimenopause: &lt;21 or &gt;35 days or &lt;8 cycles per year.</li> <li>• 1 year post menarche &gt;90 days for any 1 cycle.</li> <li>• Primary amenorrhoea by age 15 or &gt;3 years post thelarche (breast development).</li> </ul> When irregular menstrual cycles are present, a diagnosis of PCOS should be considered and assessed according to these PCOS Guidelines.	◆◆◆◆
1.1.2	PP	The mean age of menarche may differ across populations.	
1.1.3	PP	In adolescents with irregular menstrual cycles, the value and optimal timing of assessment and diagnosis of PCOS should be discussed with the patient and their parent/s or guardian/s, considering diagnostic challenges at this life stage and psychosocial and cultural factors.	
1.1.4	PP	For adolescents who have features of PCOS, but do not meet diagnostic criteria, an “increased risk” could be considered and reassessment is advised at or before full reproductive maturity, 8 years post menarche. This includes those with PCOS features before combined oral contraceptive pill (COCP) commencement, those with persisting features, and those with significant weight gain in adolescence.	
1.1.5	PP	Ovulatory dysfunction can still occur with regular cycles, and if anovulation needs to be confirmed, serum progesterone levels can be measured.	
<b>1.2</b>		<b>Biochemical hyperandrogenism</b>	
1.2.1	EBR	Healthcare professionals should use total and free testosterone to assess biochemical hyperandrogenism in the diagnosis of PCOS; free testosterone can be estimated by the calculated free androgen index.	◆◆◆◆ ⊕○○○
1.2.2	EBR	If testosterone or free testosterone is not elevated, healthcare professionals could consider measuring androstenedione and dehydroepiandrosterone sulfate (DHEAS), noting their poorer specificity and greater age-associated decrease in DHEAS.	◆◆◆ ⊕○○○
1.2.3	EBR	Laboratories should use validated, highly accurate tandem mass spectrometry (LC-MS/MS) assays for measuring total testosterone and if needed, for androstenedione and DHEAS. Free testosterone should be assessed by calculation, equilibrium dialysis, or ammonium sulfate precipitation.	◆◆◆◆ ⊕⊕○○
1.2.4	EBR	Laboratories should use LC-MS/MS assays over direct immunoassays (eg, radiometric and enzyme linked) for assessing total or free testosterone, which have limited accuracy and demonstrate poor sensitivity and precision for diagnosing hyperandrogenism in PCOS.	◆◆◆◆ ⊕⊕○○
1.2.5	PP	For the detection of hyperandrogenism in PCOS, the assessment of biochemical hyperandrogenism is of greatest value in patients with minimal or no clinical signs of hyperandrogenism (ie, hirsutism).	
1.2.6	PP	It is very difficult to reliably assess for biochemical hyperandrogenism in women on the combined oral contraceptive pill (COCP) as the pill increases sex hormone-binding globulin and reduces gonadotrophin-dependent androgen production. If already on the COCP and assessment of biochemical androgens is imperative, the pill should be withdrawn for a minimum of 3 months and contraception should be managed otherwise during this time.	
1.2.7	PP	Repeated androgen measures for the ongoing assessment of PCOS in adults have a limited role.	
1.2.8	PP	In most adolescents, androgen levels reach adult ranges at 12-15 years of age	
1.2.9	PP	If androgen levels are markedly above laboratory reference ranges, causes of hyperandrogenaemia other than PCOS, including ovarian and adrenal neoplastic growths, congenital adrenal hyperplasia, Cushing's syndrome, ovarian hyperthecosis (after menopause), iatrogenic causes, and syndromes of severe insulin resistance, should be considered. However, some androgen-secreting neoplasms are associated with only mild to moderate increases in androgen levels. The clinical history of time of onset and/or rapid progression of symptoms is critical in assessing for an androgen-secreting tumour.	
1.2.10	PP	Reference ranges for different methods and laboratories vary widely and are often based on an arbitrary percentile or variances of the mean from a population that has not been fully characterized and is highly likely to include women with PCOS. Normal values should be determined either by the range of values in a well-characterized healthy control population or by cluster analysis of general population values.	
1.2.11	PP	Laboratories involved in androgen measurements in females should consider the following: <ul style="list-style-type: none"> <li>• Determining laboratory normal values either by the range of values in a well-characterized healthy control population or by cluster analysis of the values of a large general population.</li> <li>• Applying the most accurate methods where available.</li> <li>• Using extraction/chromatography immunoassays as an alternative to mass spectrometry only where adequate expertise is available.</li> </ul>	

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
		<ul style="list-style-type: none"> <li>• Future improvements may arise from measurement of 11-oxygenated androgens and from establishing cut-off levels or thresholds based on large-scale validation in populations of different ages and ethnicities.</li> </ul>	
<b>1.3</b>		<b>Clinical hyperandrogenism</b>	
1.3.1	EBR	The presence of hirsutism alone should be considered predictive of biochemical hyperandrogenism and PCOS in adults.	◆◆◆◆ ⊕○○○
1.3.2	EBR	Healthcare professionals could recognize that female pattern hair loss and acne in isolation (without hirsutism) are relatively weak predictors of biochemical hyperandrogenism.	◆◆◆◆ ⊕○○○
1.3.3	CR	A comprehensive history and physical examination should be completed for symptoms and signs of clinical hyperandrogenism, including acne, female pattern hair loss and hirsutism in adults, and severe acne and hirsutism in adolescents.	◆◆◆◆
1.3.4	CR	Healthcare professionals should be aware of the potential negative psychosocial impact of clinical hyperandrogenism and should consider the reporting of unwanted excess hair growth and/or female pattern hair loss as being important, regardless of apparent clinical severity.	◆◆◆◆
1.3.5	CR	A modified Ferriman-Gallwey score (mFG) of 4-6 should be used to detect hirsutism, depending on ethnicity, acknowledging that self-treatment is common and can limit clinical assessment.	◆◆◆◆
1.3.6	CR	Healthcare professionals should consider that the severity of hirsutism may vary by ethnicity but the prevalence of hirsutism appears similar across ethnicities.	◆◆◆◆
1.3.7	PP	Healthcare professionals should <ul style="list-style-type: none"> <li>• Be aware that standardized visual scales are preferred when assessing hirsutism, such as the mFG scale in combination with a photographic atlas.</li> <li>• Consider the Ludwig or Olsen visual scales for assessing female pattern hair loss.</li> <li>• Note that there are no universally accepted visual instruments for assessing the presence of acne.</li> <li>• Recognize that women commonly treat clinical hyperandrogenism cosmetically, diminishing their apparent clinical severity.</li> <li>• Appreciate that self-assessment of unwanted excess hair growth, and possibly acne and female pattern hair loss, has a high degree of validity and merits close evaluation, even if overt clinical signs of hyperandrogenism are not readily evident on examination.</li> <li>• Note that only terminal hairs need to be considered in defining hirsutism, and these can reach &gt;5 mm if untreated, vary in shape and texture, and are generally pigmented.</li> <li>• Note that new-onset severe or worsening hyperandrogenism, including hirsutism, requires further investigation to rule out androgen-secreting tumours and ovarian hyperthecosis.</li> <li>• Monitor clinical signs of hyperandrogenism, including hirsutism, acne, and female pattern hair loss, for improvement or treatment adjustment during therapy.</li> </ul>	
<b>1.4</b>		<b>Ultrasound and polycystic ovarian morphology</b>	
1.4.1	EBR	Follicle number per ovary (FNPO) should be considered the most effective ultrasound marker to detect polycystic ovarian morphology (PCOM) in adults.	◆◆◆◆ ⊕⊕○○
1.4.2	EBR	Follicle number per ovary (FNPO), follicle number per cross-section (FNPS), and ovarian volume (OV) should be considered accurate ultrasound markers for PCOM in adults.	◆◆◆◆ ⊕⊕○○
1.4.3	CR	PCOM criteria should be based on follicle excess (FNPO, FNPS) and/or ovarian enlargement.	◆◆◆◆
1.4.4	CR	Follicle number per ovary (FNPO) $\geq 20$ in at least 1 ovary should be considered the threshold for PCOM in adults.	◆◆◆◆
1.4.5	CR	Ovarian volume (OV) $\geq 10$ mL or follicle number per section (FNPS) $\geq 10$ in at least 1 ovary in adults should be considered the threshold for PCOM if using older technology or image quality is insufficient to allow for an accurate assessment of follicle counts throughout the entire ovary.	◆◆◆◆
1.4.6	PP	There are no definitive criteria to define polycystic ovary morphology (PCOM) on ultrasound in adolescents; hence, it is not recommended in adolescents.	
1.4.7	PP	When an ultrasound is indicated, if acceptable to the individual, the transvaginal approach is the most accurate for the diagnosis of PCOM.	
1.4.8	PP	Transabdominal ultrasound should primarily report ovarian volume (OV) with a threshold of $\geq 10$ mL or follicle number per section (FNPS) $\geq 10$ in either ovary in adults given the difficulty of assessing follicle counts throughout the entire ovary with this approach.	
1.4.9	PP	In patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not necessary for PCOS diagnosis.	
1.4.10	PP	Thresholds for PCOM should be revised regularly with advancing ultrasound technology, and age-specific cut-off values for PCOM should be defined.	
1.4.11	PP	There is a need for training in careful and meticulous follicle counting per ovary, and clear standardized protocols are recommended for PCOM reporting on ultrasound including at a minimum the following: <ul style="list-style-type: none"> <li>• Last menstrual period (or stage of cycle).</li> <li>• Transducer bandwidth frequency.</li> <li>• Approach/route assessed.</li> <li>• Total number of 2-9 mm follicles per ovary.</li> <li>• Measurements in 3 dimensions (in cm) or volume of each ovary.</li> </ul>	

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
		<ul style="list-style-type: none"> <li>Other ovarian features and/or pathology including ovarian cysts, corpus lutea, dominant follicles (<math>\geq 10</math> mm) (which should not be included in ovarian volume calculations).</li> <li>Reliance on the contralateral ovary FNPO for diagnosis of PCOM, where a dominant follicle is noted.</li> <li>Uterine features and/or pathology including endometrial thickness and pattern.</li> </ul>	
<b>1.5</b>		<b>Anti-Müllerian hormone in the diagnosis of PCOS</b>	
1.5.1	EBR	Serum anti-Müllerian hormone (AMH) could be used for defining PCOM in adults.	◆◆◆ ⊕⊕⊕○
1.5.2	EBR	Serum AMH should only be used in accordance with the diagnostic algorithm, noting that in patients with irregular menstrual cycles and hyperandrogenism, an AMH level is not necessary for PCOS diagnosis.	◆◆◆◆ ⊕⊕⊕○
1.5.3	EBR	We recommend that serum AMH should not be used as a single test for the diagnosis of PCOS.	◆◆◆◆ ⊕⊕⊕○
1.5.4	EBR	Serum AMH should not yet be used in adolescents.	◆◆◆◆ ⊕⊕⊕○
1.5.5	PP	Either serum AMH or ultrasound may be used to define PCOM; however, both tests should not be performed to limit over-diagnosis.	
1.5.6	PP	Laboratories and healthcare professionals need to be aware of factors that influence AMH in the general population including the following: <ul style="list-style-type: none"> <li>Age: Serum AMH generally peaks between the ages of 20-25 years in the general population.</li> <li>Body mass index (BMI): Serum AMH is lower in those with higher BMI in the general population.</li> <li>Hormonal contraception and ovarian surgery: Serum AMH may be suppressed by current or recent COCP use.</li> <li>Menstrual cycle day: Serum AMH may vary across the menstrual cycle.</li> </ul>	
1.5.7	PP	Laboratories involved in AMH measurements in females should use population- and assay-specific cut-offs.	
<b>1.6</b>		<b>Ethnic variation</b>	
1.6.1	EBR	Healthcare professionals should be aware of the high prevalence of PCOS in all ethnicities and across world regions, ranging from 10% to 13% globally using the Rotterdam criteria.	◆◆◆◆ ⊕⊕○○
1.6.2	EBR	Healthcare professionals should be aware that PCOS prevalence is broadly similar across world regions but may be higher in South East Asian and Eastern Mediterranean regions.	◆◆◆◆ ⊕⊕○○
1.6.3	PP	Healthcare professionals should be aware that the presentation of PCOS may vary across ethnic groups.	
<b>1.7</b>		<b>Menopause life stage</b>	
1.7.1	CR	A diagnosis of PCOS could be considered as enduring/lifelong.	◆◆◆
1.7.2	CR	Healthcare professionals could consider that both clinical hyperandrogenism and biochemical hyperandrogenism persist in the post menopause for women with PCOS.	◆◆◆
1.7.3	CR	PCOS diagnosis could be considered post menopause if there is a past diagnosis, or a long-term history of oligo-amenorrhoea with hyperandrogenism and/or PCOM, during the earlier reproductive years (age 20-40).	◆◆◆
1.7.4	CR	Further investigations should be considered to rule out androgen-secreting tumours and ovarian hyperthecosis in postmenopausal women presenting with new-onset, severe, or worsening hyperandrogenism including hirsutism.	◆◆◆
<b>1.8</b>		<b>Cardiovascular disease risk</b>	
1.8.1	EBR	Women with PCOS should be considered at increased risk of cardiovascular disease and potentially of cardiovascular mortality, acknowledging that the overall risk of cardiovascular disease in pre-menopausal women is low.	◆◆◆ ⊕○○○
1.8.2	EBR	All women with PCOS should be assessed for cardiovascular disease risk factors.	◆◆◆◆ ⊕○○○
1.8.3	CR	All women with PCOS, regardless of age and BMI, should have a lipid profile (cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels) at diagnosis. Thereafter, the frequency of measurement should be based on the presence of hyperlipidaemia and additional risk factors or global cardiovascular risk.	◆◆◆◆
1.8.4	CR	All women with PCOS should have blood pressure measured annually and when planning pregnancy or seeking fertility treatment, given the high risk of hypertensive disorders in pregnancy and the associated comorbidities.	◆◆◆◆
1.8.5	CR	Funding bodies should recognize that PCOS is highly prevalent with multi-system effects including cardiometabolic disease and should diversify and increase research support accordingly.	◆◆◆◆
1.8.6	CR	Cardiovascular general population guidelines could consider the inclusion of PCOS as a cardiovascular risk factor.	◆◆◆
1.8.7	CR	Healthcare professionals, women with PCOS, and other stakeholders should all prioritize preventative strategies to reduce cardiovascular risk.	◆◆◆◆

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
1.8.8	PP	Consideration should be given to the differences in cardiovascular risk factors and cardiovascular disease, across ethnicities (see 1.6.1) and age, when determining frequency of risk assessment.	
<b>1.9</b>		<b>Impaired glucose tolerance and type 2 diabetes risk</b>	
1.9.1	EBR	Healthcare professionals and women with PCOS should be aware that, regardless of age and BMI, women with PCOS have an increased risk of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes.	◆◆◆◆ ⊕⊕○○
1.9.2	EBR	Glycaemic status should be assessed at diagnosis in all adults and adolescents with PCOS.	◆◆◆◆ ⊕⊕○○
1.9.3	CR	Glycaemic status should be reassessed every 1-3 years, based on additional individual risk factors for diabetes.	◆◆◆◆
1.9.4	CR	Healthcare professionals, women with PCOS, and other stakeholders should prioritize preventative strategies to reduce type 2 diabetes risk.	◆◆◆◆
1.9.5	CR	Funding bodies should recognize that PCOS is highly prevalent, has significantly higher risk for diabetes, and should be funded accordingly.	◆◆◆◆
1.9.6	CR	Diabetes general population guidelines should consider the inclusion of PCOS as an independent risk factor for diabetes.	◆◆◆◆
1.9.7	PP	Healthcare professionals, adults, and adolescents with PCOS and their first-degree relatives should be aware of the increased risk of diabetes and the need for regular glycaemic assessment.	
1.9.8	PP	Women with type 1 and type 2 diabetes have an increased risk of PCOS, and screening should be considered in individuals with diabetes.	
		<b>Glycaemic testing</b>	
1.9.9	EBR	Healthcare professionals and women with PCOS should recommend the 75-g oral glucose tolerance test (OGTT) as the most accurate test to assess glycaemic status in PCOS, regardless of BMI.	◆◆◆◆ ⊕○○○
1.9.10	EBR	If an OGTT cannot be performed, fasting plasma glucose and/or glycated haemoglobin (HbA1c) could be considered, noting significantly reduced accuracy.	◆◆◆◆ ⊕○○○
1.9.11	EBR	An OGTT should be considered in all women with PCOS and without pre-existing diabetes, when planning pregnancy or seeking fertility treatment, given the high risk of hyperglycaemia and the associated comorbidities in pregnancy. If not performed preconception, an OGTT could be offered at the first prenatal visit and all women with PCOS should be offered the test at 24-28 weeks gestation.	◆◆◆◆ ⊕○○○
1.9.12	PP	Insulin resistance is a pathophysiological factor in PCOS; however, clinically available insulin assays are of limited clinical relevance and are not recommended in routine care (refer to 3.1.10).	
<b>1.10</b>		<b>Obstructive sleep apnoea</b>	
1.10.1	EBR	Healthcare professionals should be aware that women with PCOS have significantly higher prevalence of obstructive sleep apnoea compared with women without PCOS, independent of BMI.	◆◆◆◆ ⊕⊕⊕○
1.10.2	EBR	Women with PCOS should be assessed for symptoms of obstructive sleep apnoea (ie, snoring in combination with waking un-refreshed from sleep, daytime sleepiness, or fatigue) and if present, screen with validated tools or refer for assessment.	◆◆◆◆ ⊕⊕⊕○
1.10.3	PP	Simple obstructive sleep apnoea screening questionnaires (such as the Berlin questionnaire, validated in the general population) can assist in identifying obstructive sleep apnoea in women with PCOS, noting that diagnosis requires a formal sleep study.	
1.10.4	PP	Goals of treatment should target obstructive sleep apnoea-related symptom burden.	
<b>1.11</b>		<b>Endometrial hyperplasia and cancer</b>	
1.11.1	EBR	Healthcare professionals should be aware that premenopausal women with PCOS have markedly higher risk of developing endometrial hyperplasia and endometrial cancer.	◆◆◆◆ ⊕○○○
1.11.2	PP	Women with PCOS should be informed about the increased risk of endometrial hyperplasia and endometrial cancer, acknowledging that the overall chance of developing endometrial cancer is low; therefore, routine screening is not recommended.	
1.11.3	PP	Long-standing untreated amenorrhoea, higher weight, type 2 diabetes, and persistent thickened endometrium are additional to PCOS as risk factors for endometrial hyperplasia and endometrial cancer.	
1.11.4	PP	Women with PCOS should be informed of preventative strategies including weight management, cycle regulation, and regular progestogen therapy.	
1.11.5	PP	When excessive endometrial thickness is detected, consideration of a biopsy with histological analysis and withdrawal bleed is indicated.	
<b>1.12</b>		<b>Risks in first-degree relatives</b>	
1.12.1	EBR	Healthcare professionals could consider that fathers and brothers of women with PCOS may have an increased prevalence of metabolic syndrome, type 2 diabetes, and hypertension.	◆◆◆◆ ⊕○○○
1.12.2	PP	The cardiometabolic risk in female first-degree relatives of women with PCOS remains inconclusive.	

(continued)



Table 4. Continued

No.	Type	Recommendation	Grade/quality
<b>2 Prevalence, screening, and management of psychological features and models of care</b>			
General principles			
	PP	Psychological features are common and an important component of PCOS that all healthcare professionals should be aware of.	
	PP	Funding bodies should recognize that PCOS is highly prevalent and has significantly higher psychological disorders which should be prioritized and funded accordingly.	
<b>2.1 Quality of life</b>			
2.1.1	EBR	Healthcare professionals and women should recognize the adverse impact of PCOS and/or PCOS features on quality of life in adults.	◆◆◆◆ ⊕⊕○○
2.1.2	PP	Women with PCOS should be asked about their perception of PCOS related-symptoms, impact on quality of life, key concerns, and priorities for management.	
<b>2.2 Depression and anxiety</b>			
2.2.1	EBR	Healthcare professionals should be aware of the high prevalence of moderate to severe depressive symptoms and depression in adults and adolescents with PCOS and should screen for depression in all adults and adolescents with PCOS, using regionally validated screening tools.	◆◆◆◆ ⊕⊕⊕⊕
2.2.2	EBR	Healthcare professionals should be aware of the high prevalence of moderate to severe anxiety symptoms and anxiety disorders in adults and should screen for anxiety in all adults with PCOS, using regionally validated screening tools.	◆◆◆◆ ⊕⊕⊕⊕
2.2.3	CR	If moderate or severe depressive or anxiety symptoms are detected, practitioners should further assess, refer appropriately, or offer treatment.	◆◆◆◆
2.2.4	PP	Severity of symptoms and clinical diagnosis of depression or anxiety should guide management. The optimal interval for anxiety and depression screening is not known. A pragmatic approach could include screening at diagnosis with repeat screening based on clinical judgement, risk factors, comorbidities, and life events, including the perinatal period. Screening for mental health disorders comprises assessment of risk factors, symptoms, and risk of self-harm and suicidal intent.	
<b>2.3 Psychosexual function</b>			
2.3.1	CR	Healthcare professionals could consider the multiple factors that can influence psychosexual function in PCOS including higher weight, hirsutism, mood disorders, infertility, and PCOS medications.	◆◆◆
2.3.2	CR	Permission to discuss psychosexual function should be sought noting that the diagnosis of psychosexual dysfunction requires both low psychosexual function combined with related distress.	◆◆◆◆
<b>2.4 Body image</b>			
2.4.1	EBR	Healthcare professionals should be aware that features of PCOS can have a negative impact on body image.	◆◆◆◆ ⊕⊕○○
<b>2.5 Eating disorders</b>			
2.5.1	EBR	Eating disorders and disordered eating should be considered in PCOS, regardless of weight, especially in the context of weight management and lifestyle interventions (see sections 2.4 and 3.6).	◆◆◆ ⊕⊕○○
2.5.2	PP	If disordered eating or eating disorders are suspected, appropriately qualified practitioners should further assess via a full diagnostic interview. If an eating disorder or disordered eating is detected, appropriate management and support should be offered.	
<b>2.6 Information resources, models of care, and cultural and linguistic considerations</b>			
<i>Information needs</i>			
2.6.1.1	EBR	Tailored information, education, and resources that are high quality, culturally appropriate, and inclusive should be provided to all with PCOS.	◆◆◆◆ ⊕⊕⊕○
2.6.1.2	EBR	Information, education, and resources are a high priority for patients with PCOS and should be provided in a respectful and empathic manner.	◆◆◆◆ ⊕⊕⊕○
2.6.1.3	CR	Entities responsible for healthcare professional education should ensure that information and education on PCOS is systemically embedded at all levels of healthcare professional training to address knowledge gaps.	◆◆◆◆
2.6.1.4	PP	The diversity of the population should be considered when adapting practice paradigms. Healthcare professional education opportunities should be optimised at all stages of graduate and postgraduate training and continuing professional development and in practice support resources.	
2.6.1.5	PP	Women should be counselled on the risk of misinformation and guided to evidence-based resources.	
<i>Models of care</i>			

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
2.6.2.1	CR	Models of care should prioritize equitable access to evidence-based primary care with pathways for escalation to integrated specialist and multidisciplinary services as required.	◆◆◆◆
2.6.2.2	PP	Strategies to deliver optimal models of care could include healthcare professional education, care pathways, virtual care, broader health professional engagement (eg, nurse practitioners), and coordination tools.	
2.6.3		<i>Support to manage PCOS</i>	
2.6.3.1	CR	Public health actors should consider increasing societal awareness and education on PCOS to reduce stigma and marginalization.	◆◆◆
2.6.3.2	PP	Culturally appropriate resources and education on PCOS across the lifespan for families of those with the condition should be considered.	
2.6.4		<i>Patient care</i>	
2.6.4.1	EBR	Healthcare professionals should employ shared decision-making and support patient agency or ability to take independent actions to manage their health and care.	◆◆◆◆ ⊕⊕⊕○
2.6.4.2	EBR	The importance of being knowledgeable about PCOS; of applying evidence-based practices when sharing news on diagnosis, treatment, and health implications; and of ascertaining and focusing on patient priorities should be recognized.	◆◆◆◆ ⊕⊕⊕○
2.6.4.3	CR	Healthcare system leaders should enable system-wide changes to support healthcare professional training, knowledge and practice in sharing news optimally, shared decision-making, and patient agency, including ensuring adequate consultation time and accessible resources.	◆◆◆◆
2.6.4.4	PP	Evidence-based strategies for shared decision-making and for sharing news (such as the SPIKES framework) are readily available and should be used to inform PCOS care. All healthcare professionals partnering with women with PCOS should be knowledgeable in sharing news, in shared decision-making, and in supporting patient self-management. Evidence-based strategies and resources can be used to support patient activation, which refers to modifiable knowledge, skills, ability, confidence, and willingness to self-manage one's own health and care.	
2.7		<b>Psychological therapy</b>	
2.7.1	CR	Women with PCOS diagnosed with depression, anxiety, and/or eating disorders should be offered psychological therapy guided by regional general population guidelines and the preference of the woman with PCOS.	◆◆◆◆
2.7.2	CR	Women with PCOS with disordered eating, body image distress, low self-esteem, problems with feminine identity, or psychosexual dysfunction should be offered evidence-based treatments (eg, cognitive behaviour therapy) where appropriate.	◆◆◆◆
2.8		<b>Antidepressant and anxiolytic treatment</b>	
2.8.1	CR	Psychological therapy could be considered first-line management, and antidepressant medications are considered in adults where mental health disorders are clearly documented and persistent, or if suicidal symptoms are present, based on general population guidelines.	◆◆◆
2.8.2	PP	Lifestyle intervention and other therapies (eg, COCP, metformin, and laser hair removal) that target PCOS features should be considered, given their potential to improve psychological symptoms. Where pharmacological treatment for anxiety and depression is offered in PCOS, healthcare professionals should apply caution: <ul style="list-style-type: none"> <li>To avoid inappropriate treatment with antidepressants or anxiolytics.</li> <li>To limit use of agents that exacerbate PCOS symptoms, including weight gain.</li> </ul> Healthcare professionals should be aware that not managing anxiety and depression may impact adherence to PCOS treatment/management.	
3		<b>Lifestyle management</b>	
3.1		<b>Effectiveness of lifestyle interventions</b>	
3.1.1	EBR	Lifestyle intervention (exercise alone or multicomponent diet combined with exercise and behavioural strategies) should be recommended for all women with PCOS, for improving metabolic health including central adiposity and lipid profile.	◆◆◆◆ ⊕○○○
3.1.2	CR	Healthy lifestyle behaviours encompassing healthy eating and/or physical activity should be recommended in all women with PCOS to optimize general health, quality of life, body composition, and weight management (maintaining weight, preventing weight gain, and/or modest weight loss).	◆◆◆◆
3.1.3	PP	Healthcare professionals should be aware that lifestyle management is a core focus in PCOS management.	
3.1.4	PP	Lifestyle management goals and priorities should be co-developed in partnership with women with PCOS and value women's individualized preferences.	
3.1.5	PP	There are benefits to a healthy lifestyle even in the absence of weight loss.	
3.1.6	PP	In those with higher weight, weight management can be associated with significant clinical improvements and the following key points need to be considered including the following:	

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
		<ul style="list-style-type: none"> <li>• A lifelong focus on prevention of further weight gain.</li> <li>• If the goal is to achieve weight loss, a tailored energy deficit could be prescribed for women, considering individual energy requirements, body weight, and physical activity levels.</li> <li>• The value of improvement in central adiposity (eg, waist circumference and waist-hip ratio) or metabolic health.</li> <li>• The need for ongoing assessment and support.</li> </ul>	
3.1.7	PP	Healthcare professionals should be aware of weight stigma when discussing lifestyle management with women with PCOS (see 3.6).	
3.1.8	PP	Healthy lifestyle and optimal weight management, in the context of structured, intensive, and ongoing clinical support, appears equally effective in PCOS as in the general population.	
3.1.9	PP	In those who are not overweight, in the adolescent and at key life points, the focus should be on healthy lifestyle and the prevention of excess weight gain.	
3.1.10	PP	Insulin resistance is a pathophysiological factor in PCOS; however, clinically available insulin assays are of limited clinical relevance and should not be used in routine care (refer to 1.9.12).	
<b>3.2</b>		<b>Behavioural strategies</b>	
3.2.1	CR	Lifestyle interventions could include behavioural strategies such as goal setting, self-monitoring, problem solving, assertiveness training, reinforcing changes, and relapse prevention, to optimize weight management, healthy lifestyle, and emotional well-being in women with PCOS.	◆◆◆
3.2.2	PP	Behavioural support could include: goal setting, problem solving, self-monitoring and reviewing, or SMART goals (specific, measurable, achievable, realistic, and timely).	
3.2.3	PP	Comprehensive healthy behavioural or cognitive behavioural interventions could be considered to increase support, engagement, retention, adherence, and maintenance of healthy lifestyle and improve health outcomes in women with PCOS.	
<b>3.3</b>		<b>Dietary intervention</b>	
3.3.1	EBR	Healthcare professionals and women should consider that there is no evidence to support any 1 type of diet composition over another for anthropometric, metabolic, hormonal, reproductive, or psychological outcomes.	◆◆◆ ⊕○○○
3.3.2	CR	Any diet composition consistent with population guidelines for healthy eating will have health benefits and, within this, healthcare professionals should advise sustainable healthy eating tailored to individual preferences and goals.	◆◆◆◆
3.3.3	PP	Tailoring of dietary changes to food preferences, allowing for a flexible, individual, and co-developed approach to achieving nutritional goals, and avoiding unduly restrictive and nutritionally unbalanced diets are important, as per general population guidelines.	
3.3.4	PP	Barriers and facilitators to optimize engagement and adherence to dietary change should be discussed, including psychological factors, physical limitations, socioeconomic and sociocultural factors, and personal motivators for change. The value of broader family engagement should be considered. Referral to suitably trained allied healthcare professionals needs to be considered when women with PCOS need support with optimizing their diet.	
<b>3.4</b>		<b>Exercise intervention</b>	
3.4.1	EBR	Healthcare professionals and women could consider that there is a lack of evidence supporting any 1 type and intensity of exercise being better than another for anthropometric, metabolic, hormonal, reproductive, or psychological outcomes.	◆◆◆ ⊕○○○
3.4.2	CR	Any physical activity consistent with population guidelines will have health benefits and, within this, healthcare professionals should advise sustainable physical activity based on individual preferences and goals.	◆◆◆◆
3.4.3	CR	Healthcare professionals should encourage and advise the following in concordance with general population physical activity guidelines: <ul style="list-style-type: none"> <li>• All adults should undertake physical activity as doing some physical activity is better than none.</li> <li>• Adults should limit the amount of time spent being sedentary (eg, sitting and screen time) as replacing sedentary time with physical activity of any intensity (including light intensity) provides health benefits.</li> <li>• For the prevention of weight gain and maintenance of health, adults (18-64 years) should aim for a minimum of 150-300 minutes of moderate-intensity activities or 75-150 minutes of vigorous-intensity aerobic activity per week or an equivalent combination of both spread throughout the week, plus muscle strengthening activities (eg, resistance/flexibility) on 2 non-consecutive days per week.</li> <li>• For promotion of greater health benefits including modest weight loss and prevention of weight regain, adults (18-64 years) should aim for a minimum of 250 min/week of moderate-intensity activities or 150 min/week of vigorous intensities or an equivalent combination of both, plus muscle strengthening activities (eg, resistance/flexibility) ideally on 2 non-consecutive days per week.</li> <li>• Adolescents should aim for at least 60 minutes of moderate- to vigorous-intensity physical activity per day, including activities that strengthen muscle and bone at least 3 times per week.</li> </ul>	◆◆◆◆
3.4.4	PP	Physical activity is any bodily movement produced by skeletal muscles that requires energy expenditure. It includes leisure-time physical activity, transportation (eg, walking or cycling), occupational activities (ie, work),	

(continued)

**Table 4.** Continued

No.	Type	Recommendation	Grade/quality
		household chores, playing games, sports or planned exercise, or activities in the context of daily, family, and community activities.	
3.4.5	PP	Aerobic activity is best performed in bouts of at least a 10 minute duration, aiming to achieve at least 30 minutes daily on most days.	
3.4.6	PP	Barriers and facilitators to optimize engagement and adherence to physical activity should be discussed, including psychological factors (eg, body image concerns, fear of injury, fear of failure, and mental health), personal safety concerns, environmental factors, physical limitations, socioeconomic factors, sociocultural factors, and personal motivators for change. The value of broader family engagement should be considered. Referral to suitably trained allied healthcare professionals needs to be considered for optimizing physical activity in women with PCOS.	
3.4.7	PP	Self-monitoring, including with fitness tracking devices and technologies for step count and exercise intensity, could be considered as an adjunct to support and promote active lifestyles and minimize sedentary behaviours.	
<b>3.5</b>		<b>Factors affecting weight gain in PCOS</b>	
3.5.1	EBR	Healthcare professionals and women with PCOS could consider that there is a lack of consistent evidence of physiological or behavioural lifestyle differences, related to weight, in women with PCOS compared to women without PCOS.	◆◆◆◆ ⊕○○○
3.5.2	PP	Whilst the specific mechanisms are unclear, it is recognized that many women with PCOS will have underlying mechanisms that drive greater longitudinal weight gain and higher BMI which may <ul style="list-style-type: none"> <li>• Underpin greater challenges with weight management.</li> <li>• Highlight the importance of lifelong healthy lifestyle strategies and prevention of excess weight gain.</li> <li>• Assist women with PCOS and healthcare professionals in forming realistic, tailored lifestyle goals.</li> </ul>	
<b>3.6</b>		<b>Weight stigma</b>	
3.6.1	EBR	Many women with PCOS experience weight stigma in healthcare and other settings and the negative biopsychosocial impacts of this should be recognized.	◆◆◆◆ ⊕⊕○○
3.6.2	CR	Healthcare professionals should be aware of their weight biases and the impact this has on their professional practice and on women with PCOS.	◆◆◆◆
3.6.3	CR	Health policy makers, managers, and educators should promote awareness of weight stigma and invest in weight stigma education and minimization strategies.	◆◆◆◆
3.6.4	PP	Healthcare professionals should be aware of weight-inclusive practices which promote acceptance of and respect for body size diversity and focus on improvement of health behaviours and health outcomes for people of all sizes. In PCOS, this includes the following: <ul style="list-style-type: none"> <li>• Acknowledging that whilst higher weight is a risk factor for PCOS and its complications, it is only 1 indicator of health and broader factors should be assessed.</li> <li>• Asking permission to discuss and measure weight and using strategies to minimize discomfort (eg, blind weighing).</li> <li>• Recognizing that the terms “overweight” and “obese/obesity” can be stigmatizing with suggested alternatives including “higher weight.”</li> <li>• If weighing, explaining how weight information will be used to inform risks, prevention and treatment and how not knowing may impact on recommendations.</li> <li>• Ensuring appropriate equipment is available for women of all sizes.</li> <li>• Offering options of weight-centric care (promoting intentional weight loss) or weight-inclusive care (promoting healthy lifestyle change without focusing on intentional weight loss) tailored to individual goals and preferences.</li> <li>• Offering all women best practice assessment, treatment, and support regardless of weight, acknowledging that weight may be a non-modifiable risk factor when using lifestyle modification alone.</li> </ul>	
3.6.5	PP	Increasing awareness of weight stigma among family members of women and adolescents with PCOS should be considered.	
<b>4</b>		<b>Management of non-fertility features</b>	
<b>4.1</b>		<b>Pharmacology treatment principles in PCOS</b>	
	PP	Shared decision-making between the patient (and parent/s or guardian/s, if the patient is a child) and the healthcare professional is required.	
	PP	An individual’s characteristics, preferences, and values must be elicited and considered when recommending any intervention alone or in combination.	
	PP	Understanding how individual adults and adolescents value treatment outcomes is essential when prescribing medications.	
	PP	Medical therapy is generally not approved for use specifically in PCOS, and recommended use is therefore evidence based, but off-label. Healthcare professionals need to inform adults, adolescents, and their parents/s or guardian/s and discuss the evidence, possible concerns, and side effects. Regulatory agencies should consider approval of evidence-based medications for use in PCOS.	

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
<b>4.2</b>	<b>Combined oral contraceptive pills</b>		
4.2.1	EBR	Combined oral contraceptive pills (COCP) could be recommended in reproductive age adults with PCOS for management of hirsutism and/or irregular menstrual cycles.	◆◆◆ ⊕○○○
4.2.2	EBR	The COCP could be considered in adolescents at risk or with a clear diagnosis of PCOS for management of hirsutism and/or irregular menstrual cycles.	◆◆◆ ⊕○○○
4.2.3	EBR	Healthcare professionals could consider that there is no clinical advantage of using high-dose ethinylestradiol ( $\geq 30$ $\mu$ g) versus low-dose ethinylestradiol ( $< 30$ $\mu$ g) when treating hirsutism in adults with PCOS.	◆◆◆ ⊕○○○
4.2.4	EBR	General population guidelines should be considered when prescribing COCP in adults and adolescents with PCOS as specific types or doses of progestins, oestrogens, or combinations of COCP cannot currently be recommended.	◆◆◆ ⊕○○○
4.2.5	EBR	The 35 $\mu$ g ethinyl oestradiol plus cyproterone acetate preparations should be considered as second-line therapy over other COCPs, balancing benefits and adverse effects, including venous thromboembolic risks.	◆◆◆ ⊕○○○
4.2.6	EBR	Progestin only oral contraceptives may be considered for endometrial protection, based on general population guidelines, acknowledging that evidence in women with PCOS is limited.	◆◆◆ ⊕○○○
4.2.7	PP	When prescribing COCPs in adults and adolescents with PCOS and adolescents at risk of PCOS <ul style="list-style-type: none"> <li>It is important to address main presenting symptoms and consider other treatments such as cosmetic therapies.</li> <li>Shared decision-making (including accurate information and reassurance on the efficacy and safety of COCP) is recommended and likely to improve adherence.</li> <li>Natural oestrogen preparations and the lowest effective oestrogen doses (such as 20-30 <math>\mu</math>g of ethinyl oestradiol or equivalent) need consideration, balancing efficacy, metabolic risk profile, side effects, cost, and availability.</li> <li>The relatively limited evidence on COCPs specifically in PCOS needs to be appreciated with practice informed by general population guidelines.</li> <li>The relative and absolute contraindications and side effects of COCPs need to be considered and be the subject of individualized discussion.</li> <li>PCOS-specific features, such as higher weight and cardiovascular risk factors, need to be considered.</li> </ul>	
<b>4.3</b>	<b>Metformin</b>		
4.3.1	EBR	Metformin alone should be considered in adults with PCOS and a BMI $\geq 25$ kg/m <sup>2</sup> for anthropometric and metabolic outcomes including insulin resistance, glucose, and lipid profiles.	◆◆◆ ⊕○○○
4.3.2	EBR	Metformin alone could be considered in adolescents at risk of or with PCOS for cycle regulation, acknowledging limited evidence.	◆◆◆ ⊕○○○
4.3.3	CR	Metformin alone may be considered in adults with PCOS and BMI $< 25$ kg/m <sup>2</sup> , acknowledging limited evidence.	◆◆◆
4.3.4	PP	Where metformin is prescribed, the following need to be considered: <ul style="list-style-type: none"> <li>Shared decision-making needs to consider feasibility and effectiveness of active lifestyle intervention. Women should be informed that metformin and active lifestyle intervention have similar efficacy.</li> <li>Mild adverse effects, including gastrointestinal side-effects, are generally dose dependent and self-limiting.</li> <li>Starting at a low dose, with 500 mg increments 1-2 weekly and extended-release preparations, may minimize side effects and improve adherence.</li> <li>Suggested maximum daily dose is 2.5 g in adults and 2 g in adolescents.</li> <li>Use appears safe long term, based on use in other populations; however, indications for ongoing requirement need to be considered.</li> <li>Use may be associated with low vitamin B12 levels, especially in those with risk factors for low vitamin B12 (eg, diabetes, post bariatric/metabolic surgery, pernicious anaemia, and vegan diet), where monitoring should be considered.</li> </ul>	
<b>4.4</b>	<b>Metformin and combined oral contraceptive pills</b>		
4.4.1	EBR	COCP could be used over metformin for management of hirsutism in irregular menstrual cycles in PCOS.	◆◆◆ ⊕○○○
4.4.2	EBR	Metformin could be used over COCP for metabolic indications in PCOS.	◆◆◆ ⊕○○○
4.4.3	EBR	The combination of COCP and metformin could be considered to offer little additional clinical benefit over COCP or metformin alone, in adults with PCOS with a BMI $\leq 30$ kg/m <sup>2</sup> .	◆◆◆ ⊕○○○
4.4.4	PP	In combination with the COCP, metformin may be most beneficial in high metabolic risk groups including those with a BMI $> 30$ kg/m <sup>2</sup> , diabetes risk factors, impaired glucose tolerance, or high-risk ethnic groups.	
4.4.5	PP	Where COCP is contraindicated, not accepted, or not tolerated, metformin may be considered for irregular menstrual cycles. For hirsutism, other interventions may be needed.	
<b>4.5</b>	<b>Anti-obesity pharmacological agents</b>		
4.5.1	CR	Anti-obesity medications, including liraglutide, semaglutide, and both glucagon-like peptide-1 (GLP-1) receptor agonists and orlistat, could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines.	◆◆◆

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
4.5.2	PP	Healthcare professionals should ensure concurrent effective contraception when pregnancy is possible for women who take GLP-1 receptor agonists, as pregnancy safety data are lacking.	
4.5.3	PP	Gradual dose escalation for GLP-1 receptor agonists is recommended to reduce gastrointestinal adverse effects.	
4.5.4	PP	Shared decision-making, when discussing GLP-1 receptor agonist use with women with PCOS, needs to consider side effects and the potential need for long-term use in weight management, given the high risk for weight regain after discontinuation and the lack of long-term safety data.	
<b>4.6</b>	<b>Anti-androgen pharmacological agents</b>		
4.6.1	EBR	In combination with effective contraception, anti-androgens could be considered to treat hirsutism in women with PCOS, if there is a suboptimal response after a minimum of 6 months of COCP and/or cosmetic therapy.	◆◆◆ ⊕○○○
4.6.2	CR	Given the negative psychological impact of female pattern hair loss, anti-androgens in combination with COCP could be trialled, acknowledging the lack of evidence in the PCOS population.	◆◆◆
4.6.3	PP	Whenever pregnancy is possible, healthcare professionals must educate and counsel women and adolescents, parents/s or guardian/s, regarding the risks of incomplete development of external genital structures of male foetuses (undervirilization) when anti-androgens are used. To prevent this, women who can get pregnant should be strongly counselled to use effective contraception (eg, intrauterine device or COCPs).	
4.6.4	PP	Anti-androgens could be considered to treat hirsutism, in the presence of another effective form of contraception, for women with contraindications for COCP therapy or when COCPs are poorly tolerated.	
4.6.5	PP	When prescribing anti-androgens, based on general population recommendations, healthcare professionals should consider that <ul style="list-style-type: none"> <li>• Spironolactone at 25-100 mg/day appears to have lower risks of adverse effects.</li> <li>• Cyproterone acetate at doses <math>\geq 10</math> mg is not advised due to an increased risk including for meningioma.</li> <li>• Finasteride has an increased risk of liver toxicity.</li> <li>• Flutamide and bicalutamide have an increased risk of severe liver toxicity.</li> <li>• The relatively limited evidence on anti-androgens in PCOS needs to be appreciated with small numbers of studies and limited numbers of participants.</li> </ul>	
<b>4.7</b>	<b>Inositol</b>		
4.7.1	EBR	Inositol (in any form) could be considered in women with PCOS based on individual preferences and values, noting limited harm, potential for improvement in metabolic measures, yet with limited clinical benefits including in ovulation, hirsutism, or weight.	◆◆◆ ⊕○○○
4.7.2	EBR	Metformin should be considered over inositol for hirsutism and central adiposity, noting that metformin has more gastrointestinal side effects than inositol.	◆◆◆ ⊕○○○
4.7.3	PP	Women taking inositol and other complementary therapies are encouraged to advise their healthcare professional.	
4.7.4	PP	Specific types, doses, or combinations of inositol cannot currently be recommended in adults and adolescents with PCOS, due to a lack of quality evidence.	
4.7.5	PP	Shared decision-making should include discussion that regulatory status and quality control of inositol in any form (like other nutrient supplements) can differ from those for pharmacological products and doses and qualities may vary.	
4.7.6	PP	Policy makers and healthcare professionals have a responsibility to ensure women have access to unconflicted, evidence-based information to inform shared decision-making, whilst also acknowledging and respecting individual values and preferences, including for complementary therapies.	
<b>4.8</b>	<b>Mechanical laser and light therapies for hair reduction</b>		
4.8.1	EBR	Mechanical laser and light therapies should be considered for reducing facial hirsutism and for related depression, anxiety, and quality of life in women with PCOS.	◆◆◆ ⊕○○○
4.8.2	EBR	A greater number of laser treatment sessions may be required in women with PCOS, compared with women with idiopathic hirsutism, to achieve hair reduction.	◆◆◆ ⊕○○○
4.8.3	CR	Adverse effects appear limited in the hands of experienced and suitably qualified providers, and women should be encouraged to seek hair reduction therapies from such providers.	◆◆◆◆
4.8.4	PP	Where laser hair removal is prescribed, the following need to be considered: <ul style="list-style-type: none"> <li>• Wavelength and delivery of laser treatment vary by skin and hair colour.</li> <li>• Laser is relatively ineffective in women with blond, grey, or white hair.</li> <li>• The addition of combined oral contraceptive pills (COCP), with or without anti-androgens, to laser treatment may provide greater hair reduction and maintenance compared to laser alone.</li> <li>• Low- and high-fluence lasers appear to have similar efficacy in reducing facial hair, while low-fluence laser has reduced associated pain.</li> </ul>	
4.8.5	PP	Mechanical hair removal with Intense Pulse Light (IPL) could be considered, albeit benefits may be less pronounced compared to laser treatment. There is no evidence to support the efficacy of home-based IPL kits.	

(continued)



Table 4. Continued

No.	Type	Recommendation	Grade/quality
4.8.6	PP	Policy makers should consider funding this evidence-based effective therapy for women with PCOS to alleviate distressing symptoms of hirsutism and related negative impact on quality of life, body image, and psychological health.	
<b>4.9</b>		<b>Bariatric/metabolic surgery</b>	
4.9.1	CR	Bariatric/metabolic surgery could be considered to improve weight loss, hypertension, diabetes (prevention and treatment), hirsutism, irregular menstrual cycles, ovulation, and pregnancy rates in women with PCOS.	◆◆◆
4.9.2	CR	Bariatric/metabolic surgery in women with PCOS should be informed by general population guidelines.	◆◆◆◆
4.9.3	CR	PCOS is a metabolic condition and could be considered an indication at a lower BMI threshold for bariatric/metabolic surgery similarly to other metabolic conditions including diabetes.	◆◆◆
4.9.4	CR	Women should be strongly counselled on the likelihood of rapid return of fertility and the need to commit to effective contraception, ideally prior to surgery. Even when pregnancy is desired, contraception should be continued until a stable weight is achieved, usually after 1 year, to avoid significantly increased risk of growth restriction, prematurity, small for gestational age, pregnancy complications, and prolonged hospitalization of the infant.	◆◆◆◆
<b>4.10</b>		<b>Pregnancy outcomes</b>	
4.10.1	EBR	Women with PCOS have higher risk pregnancies, and healthcare professionals should ensure that PCOS status is identified during antenatal care, and appropriate monitoring and support are provided.	◆◆◆◆ ⊕○○○
4.10.2	EBR	Healthcare professionals should recognize that pregnant women with PCOS have an increased risk of the following: <ul style="list-style-type: none"> <li>• Higher gestational weight gain.</li> <li>• Miscarriage.</li> <li>• Gestational diabetes.</li> <li>• Hypertension in pregnancy and preeclampsia.</li> <li>• Intrauterine growth restriction, small for gestational age babies, and low birth weight.</li> <li>• Preterm delivery.</li> <li>• Caesarean section.</li> </ul>	◆◆◆◆ ⊕○○○
4.10.3	EBR	Assisted reproductive technology in women with PCOS should be considered as not conferring additional risk of miscarriage, preterm birth, impaired foetal growth, and caesarean section, over that observed in women without PCOS.	◆◆◆ ⊕○○○
4.10.4	EBR	Women with PCOS should be considered as not having an increased risk of large for gestational age babies, macrosomia, and instrumental delivery.	◆◆◆ ⊕○○○
4.10.5	PP	Early lifestyle intervention should be offered to pregnant women with PCOS, given the risk of higher baseline weight, excess gestational weight gain, and pregnancy complications.	
4.10.6	PP	Blood pressure measurement should be performed when planning pregnancy or seeking fertility treatment, given the high risk of hypertensive disorders in pregnancy and the associated comorbidities in women with PCOS.	
4.10.7	PP	An OGTT should be offered to all women with PCOS when planning pregnancy or seeking fertility treatment, given the high risk of hyperglycaemia and the associated comorbidities in pregnancy. If not performed in the preconception phase, an OGTT should be offered at the first antenatal visit and repeated at 24-28 weeks gestation.	
<b>4.11</b>		<b>Metformin in pregnancy</b>	
4.11.1	EBR	Healthcare professionals should be aware that metformin in pregnant women with PCOS has not been shown to prevent the following: <ul style="list-style-type: none"> <li>• Gestational diabetes.</li> <li>• Late miscarriage (12 weeks + 1 day to 21 weeks + 6 days gestational age).</li> <li>• Hypertension in pregnancy.</li> <li>• Preeclampsia.</li> <li>• Macrosomia or birthweight <math>\geq 4000</math> g.</li> </ul>	◆◆◆◆ ⊕⊕○○
4.11.2	EBR	Metformin could be considered in some circumstances (eg, risk for preterm birth) to reduce preterm delivery and limit excess gestational weight gain, in pregnant women with PCOS.	◆◆◆ ⊕⊕⊕○
4.11.3	PP	Women should be counselled that the consequences of metformin exposure on long-term offspring health remain unclear and there is a suggestion of increased childhood weight, although causality is not certain.	
4.11.4	PP	Side effects of metformin are mostly mild, transient gastrointestinal symptoms and are not worse in pregnancy.	
<b>5</b>		<b>Assessment and treatment of infertility</b>	
		General principles	
	PP	All fertility treatment in PCOS should be guided by the fertility treatment algorithm (Algorithm 2).	
	PP	Those with PCOS should be reassured that pregnancy can often be successfully achieved either naturally or with assistance.	

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
	PP	Prenatal vitamin supplementation should be commenced with ovulation induction therapy aligned to routine preconception care.	
	PP	Pregnancy should be excluded prior to ovulation induction therapy.	
	PP	The use of ovulation induction agents, including letrozole, metformin, and clomiphene citrate, is off-label in many countries. Where off-label use of ovulation induction agents is allowed, healthcare professionals need to inform women and discuss the evidence, possible concerns, and side effects.	
	PP	There should be ongoing monitoring of patients for adverse effects and infants for congenital anomalies, in all studies conducted with ovulation induction agents, and these should be reported in any published papers.	
<b>5.1</b>	<b>Preconception risk factors</b>		
5.1.1	EBR	Women with PCOS should be counselled on the adverse impact of excess weight on clinical pregnancy, miscarriage, and live birth rates, following infertility treatment.	◆◆◆◆ ⊕○○○
5.1.2	CR	Consistent with routine preconception care, in women with PCOS planning pregnancy, weight, blood pressure, smoking, alcohol, diet and nutritional status, folate supplementation (higher dose in those with BMI > 30 kg/m <sup>2</sup> ), exercise, sleep, and mental, emotional, and sexual health should be considered and optimized to improve reproductive and pregnancy outcomes and overall health.	◆◆◆◆
5.1.3	PP	A reproductive life plan and age-appropriate education on optimizing reproductive health is recommended in adolescents and women with PCOS, including healthy lifestyle, prevention of excess weight gain, and optimizing preconception risk factors.	
5.1.4	PP	Healthcare professionals are encouraged to seek permission and, if given, to assess weight and BMI and initiate a dialogue on the importance of weight and lifestyle on women's health before pregnancy. This requires caution to avoid weight stigma and needs to consider the cultural, social, and environmental determinants of health (see 3.6).	
5.1.5	PP	Chronic conditions, such as diabetes, high blood pressure, anxiety, depression, and other mental health conditions, should be optimally managed, and women should be counselled regarding the risk of adverse pregnancy outcomes.	
<b>5.2</b>	<b>Tubal patency testing</b>		
5.2.1	CR	In women with PCOS and infertility due to anovulation alone with normal semen analysis, the risks, benefits, costs and timing, and techniques of tubal patency testing in relation to the cost and complexity of the treatment should be considered on an individual basis, depending on personal history and population prevalence, prior to starting ovulation induction with timed intercourse or intrauterine insemination.	◆◆◆
<b>5.3</b>	<b>Letrozole</b>		
5.3.1	EBR	Letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS, with no other infertility factors.	◆◆◆◆ ⊕⊕⊕⊕
5.3.2	PP	The use of letrozole is still off-label in many countries. Where it is not allowed, clinicians could use other ovulation induction agents.	
5.3.3	PP	Letrozole should not be given where there is any possibility of a pre-existing pregnancy, though there is no evidence for increased teratogenicity compared to other ovulation induction agents.	
<b>5.4</b>	<b>Clomiphene citrate and metformin</b>		
<b>5.4.1</b>	<i>Metformin versus placebo</i>		
5.4.1.1	EBR	Metformin could be used alone, in women with PCOS with anovulatory infertility and no other infertility factors, to improve clinical pregnancy and live birth rates, whilst informing women that there are more effective ovulation agents.	◆◆◆ ⊕⊕○○
5.4.1.2	PP	Women should be counselled as to potential mild gastrointestinal side-effects with metformin.	
5.4.1.3	PP	Healthcare and resource burden including monitoring, travel, and costs are lower with metformin.	
5.4.1.4	PP	Consideration of age and screening for other fertility factors needs to be discussed before prescribing metformin.	
<b>5.4.2</b>	<i>Clomiphene citrate versus metformin</i>		
5.4.2.1	EBR	Clomiphene citrate could be used in preference to metformin in women with PCOS with anovulatory infertility and no other infertility factors, to improve ovulation, clinical pregnancy, and live birth rates.	◆◆◆ ⊕⊕○○
5.4.2.2	PP	The risk of multiple pregnancies is increased with clomiphene citrate use (alone or in combination with metformin), and therefore, clomiphene cycles may require ultrasound monitoring.	
<b>5.4.3</b>	<i>Clomiphene citrate and metformin versus clomiphene citrate alone</i>		
5.4.3.1	EBR	Clomiphene citrate combined with metformin could be used rather than clomiphene citrate alone in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation and clinical pregnancy rates.	◆◆◆ ⊕⊕○○
<b>5.4.4</b>	<i>Clomiphene citrate and metformin versus metformin alone</i>		

(continued)

Table 4. Continued

No.	Type	Recommendation	Grade/quality
5.4.4.1	EBR	Clomiphene citrate combined with metformin could be used rather than metformin alone in women with PCOS with anovulatory infertility and no other infertility factors to improve live birth rates.	◆◆◆ ⊕⊕○○
5.4.4.2	PP	Monitoring of combined cycles will need to be equivalent to clomiphene citrate alone.	
5.4.5		<i>Clomiphene citrate versus Letrozole</i>	
5.4.5.1	EBR	Letrozole should be used rather than clomiphene citrate in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation, clinical pregnancy, and live birth rates.	◆◆◆◆ ⊕○○○
5.4.5.2	PP	Current evidence demonstrates no difference in foetal abnormality rates between letrozole or clomiphene citrate ovulation induction or natural conception.	
5.5		<b>Gonadotrophins</b>	
5.5.1	EBR	Gonadotrophins alone could be considered rather than clomiphene citrate in therapy naïve women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation, clinical pregnancy, and live birth rates (refer to PP 5.5.6).	◆◆◆ ⊕⊕○○
5.5.2	EBR	Gonadotrophins alone could be used over gonadotrophins combined with clomiphene citrate in women with PCOS who are anovulatory and infertile with clomiphene citrate resistance or failure and no other infertility factors.	◆◆◆ ⊕⊕○○
5.5.3	EBR	Gonadotrophins could be considered rather than the combination of clomiphene citrate and metformin in women with PCOS who are anovulatory and infertile, with clomiphene citrate resistance and no other infertility factors.	◆◆◆ ⊕○○○
5.5.4	EBR	Either gonadotrophins or laparoscopic ovarian surgery could be used in women with PCOS who are anovulatory and infertile, with clomiphene citrate resistance and no other infertility factors, following counselling on higher live birth rate and higher multiple pregnancy rates with gonadotrophins.	◆◆ ⊕⊕○○
5.5.5	EBR	Gonadotrophins could be second-line pharmacological therapy for women with PCOS who are anovulatory and infertile, with no other infertility factors and who have failed first line oral ovulation induction.	◆◆◆ ⊕⊕○○
5.5.6	PP	Where gonadotrophins are to be prescribed, the following should be considered: <ul style="list-style-type: none"> <li>• Cost of the intervention for ovulation induction.</li> <li>• Expertise required for the use of the intervention for ovulation induction.</li> <li>• The degree of intensive ultrasound monitoring that is required.</li> <li>• A low-dose step-up gonadotrophin protocol should be used to optimize the chance of monofollicular development.</li> <li>• Implications of potential multiple pregnancy.</li> </ul>	
5.5.7	PP	There appears to be no difference in the clinical efficacy of the available gonadotrophin preparations.	
5.5.8	PP	When using gonadotrophins, the best clinical practice is to avoid multiple pregnancies. Considerations here include cancelling cycles when there is more than a total of 2 follicles greater than 14 mm in diameter and advising avoidance of unprotected intercourse.	
5.5.9	PP	Live birth rate, clinical pregnancy rate per patient, and ovulation rate per cycle are higher with gonadotrophins than with clomiphene citrate.	
5.5.10	PP	A low-dose gonadotrophin protocol should be used to optimize the chance of monofollicular growth and minimize multiple pregnancies.	
5.5.11	PP	Cycle monitoring and drug costs coupled with multiple injections will influence the choice in gonadotrophin use.	
5.6		<b>Laparoscopic ovarian surgery</b>	
5.6.1	EBR	Laparoscopic ovarian surgery could be second-line therapy for women with PCOS who are anovulatory and infertile, with clomiphene citrate resistance and no other infertility factors.	◆◆◆ ⊕⊕○○
5.6.2	PP	When using laparoscopic ovarian surgery, the following should be considered: <ul style="list-style-type: none"> <li>• Comparative cost of the intervention for ovulation induction.</li> <li>• Expertise required for the safe use of the intervention for ovulation induction.</li> <li>• Both intraoperative and postoperative risks, which are higher in women who are above healthy weight.</li> </ul>	
5.7		<b><i>In vitro</i> fertilization and <i>in vitro</i> maturation</b>	
5.7.0.1	CR	In the absence of an absolute indication for <i>in vitro</i> fertilization (IVF)/intracytoplasmic sperm injection (ICSI), IVF could be offered in women with PCOS and anovulatory infertility, if first- or second-line ovulation induction therapies have failed.	◆◆◆
5.7.0.2	PP	In women with anovulatory PCOS, the use of IVF is effective and when elective single-embryo transfer is used, multiple pregnancies can be minimized.	
5.7.0.3	PP	Women with PCOS undergoing IVF/ICSI treatment should be counselled prior to starting treatment about the increased risk of ovarian hyperstimulation syndrome and options to reduce the risk should be offered.	
5.7.1		<b><i>Gonadotrophin releasing hormone protocol</i></b>	
5.7.1.1	PP	Gonadotrophin-releasing hormone (GnRH) antagonist protocol cannot be recommended over GnRH agonist long protocol for women with PCOS undergoing IVF/ICSI to improve clinical pregnancy or live birth rate.	


(continued)

**Table 4.** Continued

No.	Type	Recommendation	Grade/quality
5.7.1.2	PP	The use of a GnRH antagonist protocol for women with PCOS undergoing IVF/ICSI is recommended as it enables the use of an agonist trigger, with the freezing of all embryos generated if required, without compromising the cumulative live birth rate, to reduce the risk of significant ovarian hyperstimulation syndrome.	
5.7.2		<i>Trigger type</i>	
5.7.2.1	CR	Triggering final oocyte maturation with a GnRH agonist and freezing all suitable embryos are recommended, in an IVF/ICSI cycle with a GnRH antagonist protocol, where a fresh embryo transfer is not intended or where there is an increased risk of ovarian hyperstimulation syndrome.	◆◆◆◆
5.7.3		<i>Choice of follicle stimulating hormone</i>	
5.7.3.1	CR	Either urinary or recombinant follicle stimulating hormone (FSH) could be used in women with PCOS undergoing (controlled) ovarian (hyper) stimulation for IVF/ICSI, with insufficient evidence to recommend a particular type of FSH preparation.	◆◆◆
5.7.4		<i>Exogenous luteinising hormone</i>	
5.7.4.1	CR	Exogenous recombinant luteinising hormone (LH) treatment should not be routinely used in combination with FSH therapy in women with PCOS undergoing controlled ovarian hyperstimulation for IVF/ICSI.	◆
5.7.5		<i>Adjunct metformin</i>	
5.7.5.1	EBR	Adjunct metformin therapy could be used before and/or during FSH ovarian stimulation in women with PCOS undergoing IVF/ICSI treatment with GnRH agonist long protocol, to reduce the risk of developing ovarian hyperstimulation syndrome and miscarriage.	◆◆◆ ⊕⊕○○
5.7.5.2	PP	Good practice in PCOS and IVF is the use of a GnRH antagonist protocol as it gives the flexibility of using a GnRH agonist trigger, freezing all strategy to reduce the risk of ovarian hyperstimulation syndrome. However, if using a GnRH agonist long protocol, then metformin could be considered. If using metformin, the following could be considered: <ul style="list-style-type: none"> <li>• Commence metformin at the start of GnRH agonist treatment.</li> <li>• Gradually titrate metformin up to a dose of between 1000 and 2500 mg daily in order to minimize side effects.</li> <li>• Stopping metformin therapy at the time of the pregnancy test or period, unless the metformin therapy is otherwise indicated.</li> </ul>	
5.7.6		<i>In vitro maturation</i>	
5.7.6.1	EBR	The use of in vitro maturation (IVM) and ICSI could be considered in women with PCOS as an alternative to a stimulated IVF/ICSI cycle, where an embryo is frozen and replaced in a subsequent embryo transfer cycle, acknowledging there is no risk of ovarian hyperstimulation syndrome, but a lower cumulative live birth rate.	◆◆ ⊕⊕⊕○
5.7.6.2	CR	The use of IVM and ICSI could be considered prior to stimulated IVF/ICSI cycles acknowledging both benefits and limitations.	◆◆
5.7.6.3	PP	IVM should only be considered in services with sufficient expertise, and advocacy is needed for regional or national centres of expertise.	
5.7.6.4	PP	IVM could be offered as an option in women with prior severe ovarian hyperstimulation syndrome and where the risk of severe ovarian hyperstimulation syndrome is deemed unacceptably high, provided that expertise in IVM techniques exists.	
5.7.6.5	PP	Evidence suggests that IVM/ICSI is less effective than standard IVF/ICSI in terms of clinical pregnancy per patient and live birth rate per patient.	
5.8		<b>Inositol</b>	
5.8.1	EBR	Inositol in any form alone, or in combination with other therapies, should be considered experimental therapy in women with PCOS with infertility, with benefits and risks currently too uncertain to recommend the use of these agents as fertility therapies.	◆◆◆ ⊕○○○
5.8.2	PP	There is limited evidence with uncertain results, on the effect of inositol on ovulation, clinical pregnancy, and live birth rates.	
5.8.3	PP	Side effects and safety are not known for inositol.	
5.8.4	PP	Women need to be aware that these agents can have limited regulation with variable dose, quality, consistency, and combination with other agents.	
5.8.5	PP	Women's personal goals and preferences should be considered when discussing complimentary therapies.	
5.9		<b>Anti-obesity pharmacological agents</b>	
5.9.1	CR	We recommend using anti-obesity agents in PCOS for reproductive outcomes only in research settings to establish the efficacy and safety.	

See Table 1 for the definition of CR, EBR, and PP.

© International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University (monash.edu/medicine/mchri/pcos), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re use, please contact the rights holder.

**Algorithm 1: Diagnostic algorithm for polycystic ovary syndrome (PCOS)**

**Figure 1.** Algorithm 1—Diagnostic algorithm for polycystic ovary syndrome (PCOS). © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University ([monash.edu/medicine/mchri/pcos](https://monash.edu/medicine/mchri/pcos)), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re use, please contact the rights holder. \*Exclusion of other causes = TSH, prolactin, 17-OH progesterone, FSH or if clinically indicated exclude other causes (eg, Cushing's syndrome, adrenal tumours). For hypogonadotropic hypogonadism, usually due to low body fat or intensive exercise, exclude clinically and with LH and FSH levels. TSH, thyroid stimulating hormone.

Combined oral contraceptive pills are the first line pharmacological treatment for menstrual irregularity and hyperandrogenism, with no specific recommended preparation and a preference for lower ethinyl estradiol dose preparations and those with less side-effects. Metformin is recommended primarily for metabolic features and has greater efficacy than inositol, which offers limited clinical benefits in PCOS. Metformin is not routinely recommended for use in pregnant women with PCOS. Mechanical laser therapy is effective for hair reduction in some subgroups, whilst anti-androgens have a limited role where other therapies are ineffective or contraindicated. Anti-obesity agents and bariatric/metabolic surgery may be considered based on general population guidelines, balancing potential for benefits and side effects.

Letrozole is the preferred first line pharmacological infertility therapy, with clomiphene in combination with metformin; gonadotrophins or ovarian surgery primarily having a role as second line therapy. *In vitro* fertilization (IVF) could be offered, potentially with *in vitro* maturation, as third line therapy, where other ovulation induction therapies have failed and in the absence of an absolute indication for IVF in women with PCOS and anovulatory infertility. Given the underlying risk for pregnancy complications in PCOS, single embryo transfer should be preferred.

Overall, evidence in PCOS is low to moderate quality. Based on high prevalence and significant health impact, greater priority, education, models of care, funding, and research are recommended. Guideline translation will be extensive including multilingual education outputs and evidence-based resources for consumers (the ASKPCOS app), healthcare professionals and policy makers.

The guideline recommendations are protected under copyright, however a clear process for adaption of guideline recommendations to regional context is available by contacting the author for correspondence online ([www.monash.edu/medicine/mchri/pcos](https://www.monash.edu/medicine/mchri/pcos)). The translation program will be free and internationally accessible, building on the existing range of codesigned resources including the patient focused, evidence-based PCOS APP (AskPCOS), used in 186 countries and based on a rigorously developed question prompt list. Multi-faceted patient codesigned resources will aim to enhance health literacy with comprehensive PCOS-related health information available in multiple formats and in 15–20 languages. Internationally

accessible resources include education modules for healthcare professionals at different career stages and disciplines, healthcare professional accredited courses, practice resources and tools, webinars with international expert panels, and e-health information resources that will be available online ([www.monash.edu/medicine/mchri/pcos](https://www.monash.edu/medicine/mchri/pcos)). Importantly, the Guideline and translation of the Guideline is expected to improve patient experiences through the provision of timely and accurate diagnosis, of accessible evidence-based information and of improved multi-disciplinary support. Ultimately, this international initiative may serve as an exemplar for large scale collaborative engagement, pooling of resources, avoidance of duplication and inconsistency with consensus-based statements, and codesign of best quality consistent guidelines with processes for local adaption and healthcare impact. Key elements include extensive collaboration, broad stakeholder representation, consumer partnership, distributive leadership, adequate funding, robust project management and governance, adherence to best practice and integrated comprehensive translation, and evaluation. We sincerely thank the partner and collaborating organizations, consumer groups and members of the GDGs for their substantive commitment to the international partnership to optimize health outcomes for women with this common, heterogeneous, and much neglected condition.

## Acknowledgments

We gratefully acknowledge contribution of our partners and collaborating organizations:


The Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Women's Health in Reproductive Life (CRE WHiRL) (APP1171592), Centre for Research Excellence in Polycystic Ovary Syndrome (CRE PCOS) (APP1078444) and the members of these Centres who coordinated this international guideline effort.

Our partner and co-funding organizations are:

American Society for Reproductive Medicine (ASRM)  
Endocrine Society (ENDO)  
European Society for Endocrinology (ESE)

**Algorithm 2: Infertility algorithm for polycystic ovary syndrome (PCOS)**

Central Blue Pathway follows best practice evidence and is preferred



**Figure 2.** Algorithm 2—Infertility algorithm for polycystic ovary syndrome (PCOS). © Monash University on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life, 2023. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023, Helena Teede et al. Monash University ([monash.edu/medicine/mchri/pcos](https://monash.edu/medicine/mchri/pcos)), 2023, by permission of Monash University, on behalf of the NHMRC Centre for Research Excellence in Women's Health in Reproductive Life. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission re reuse, please contact the rights holder. Central blue pathway follows best practice evidence and is preferred.

European Society of Human Reproduction and Embryology (ESHRE)

Collaborating and engaged societies and consumer providing in-kind support include:

Androgen Excess and Polycystic Ovary Syndrome Society (AEPPOS)

Asia Pacific Paediatric Endocrine Society (APPES)

Asia Pacific Initiative on Reproduction (ASPIRE)

Australia and New Zealand Society for Paediatric Endocrinology and Diabetes (ANZSPED)

Australian Diabetes Society (ADS)

Brazilian Society of Endocrinology and Metabolism (SBEM)

British Fertility Society (BFS)

Canadian Society of Endocrinology and Metabolism (CSEM)

Dietitians Association Australia (DA)

Endocrine Society Australia (ESA)

European Society for Paediatric Endocrinology (ESPE)



Exercise and Sports Science Australia (ESSA)  
 Fertility Society Australia and New Zealand (FSA)  
 International Federation of Fertility Societies (IFFS)  
 International Federation of Gynecology and Obstetrics (FIGO)  
 International Society of Endocrinology (ISE)—40 partner societies  
 Italian Society of Gynaecology and Obstetrics  
 Japanese Society for Paediatric Endocrinology (JSPE)  
 Latin American Society for Paediatric Endocrinology (SLEP)  
 Nordic Federation of Societies of Obstetrics and Gynaecology (NFOG)  
 PCOS Challenge Inc: The National Polycystic Ovary Syndrome Association  
 PCOS Society of India  
 PCOS Vitality  
 Paediatric Endocrine Society (PES)  
 Royal Australasian College of Physicians (RACP)  
 Royal Australian New Zealand College of Obstetricians and Gynaecologists (RANZCOG)  
 Royal Australian and New Zealand College of Radiologists (RANZCR)  
 Royal College of Obstetricians and Gynaecologists (RCOG)  
 Society for Endocrinology  
 South African Society of Gynaecology and Obstetrics (SASOG)  
 Verity UK  
 Victorian Assisted Reproductive Technology Association (VARTA)  
 Other relevant organizations are welcome to apply to partner in guideline translation.

## Funding

The Australian National Health Medical Research Council (NHMRC) (APP1171592) primarily funded this work. The American Society for Reproductive Medicine, Endocrine Society, the European Society of Human Reproduction and Embryology and the European Society for Endocrinology provided partnership funding. Collaborating organizations provided in-kind support. The Commonwealth Government of Australia also supported Guideline Translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships and CTT by an RACP fellowship.

## Author Contributions

HJT led the guidelines from funding, engaging partners, coordinating processes, prioritizing clinical questions, co-chairing guideline meetings, coordinating peer review responses and leading writing, approval and publication processes. Listed authors held senior leadership roles as chair or deputy chair of the five GDGs or leadership of the evidence team with roles from the management committee, chair/co-chair of GDG or the early career evidence network, involvement at all stages, responding to feedback, providing input into and endorsing the guideline. All other included authors were actively engaged as partner nominees and multidisciplinary GDG or consumer experts. The evidence synthesis network was led by CTT AM, across search strategies, training, Covidence processes, quality appraisal and GRADE, meta-analysis, evidence integrity processes (with BM) and preparing

the technical report. The listed members of this network led evidence synthesis across the clinical questions and had input into the technical report.

## Disclosures

Disclosures of interest were declared at the outset and updated throughout the guideline process, aligned with National Health Medical Research Council (NHMRC) guideline processes. These are available online ([www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittell GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim.

## Data Availability

All data extracted and analyzed in the guideline is available in a repository and can be accessed via <https://doi.org/10.26180/23625288.v1>

## Appendix

### Members of the PCOS Network:

The international advisory panel, guideline technical team, paediatric, consumer and translation committees, the Indigenous cultural advisor and the extended early career support network who assisted with evidence synthesis, can be found online ([www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)).

### Guideline Development Members and Key Contributors (in Addition to Listed Authors)

Wiebke Arlt, University of Birmingham, UK  
 Ricardo Azziz, University of Alabama at Birmingham, USA  
 Adam Balen, Leeds Teaching Hospital; British Fertility Society, UK  
 Lisa Bedson, Repromed, Australia  
 Lorna Berry, Polycystic Ovary Syndrome Association of Australia, Australia  
 Jacky Boivin, Cardiff University, UK  
 Leah Brennan, Latrobe University, Australia  
 Wendy Brown, Monash University, Australia  
 Tania Burgert, University Missouri—Kansas School of Medicine, USA  
 Maureen Busby, PCOS Vitality, Ireland  
 Carolyn Ee, Western Sydney University, Australia

Rhonda M. Garad, Monash University, Australia  
 Melanie Gibson-Helm, Te Tātai Hauora o Hine, Victoria University of Wellington; NZ  
 Cheryce Harrison, Monash University, Australia  
 Roger Hart, The University of Western Australia; City Fertility, Australia  
 Kim Hopkins, PCOS Challenge: National Polycystic Ovary Syndrome Association, USA  
 Angelica Lindén Hirschberg, Karolinska Institutet, Karolinska University Hospital, Sweden  
 Tuong Ho, HOPE Research Centre, My Duc Hospital, Vietnam  
 Kathleen Hoeger, University of Rochester, USA  
 Cailin Jordan, Genea Hollywood Fertility, Australia  
 Richard S. Legro, Penn State Clinical and Translational Institute, USA  
 Rong Li, Peking University Third Hospital, China  
 Marla Lujan, Cornell University, USA  
 Ronald Ma, Chinese University of Hong Kong, Hong Kong /China  
 Darren Mansfield, Monash and Epworth Health, Monash University, Australia  
 Kate Marsh, Northside Nutrition & Dietetics, Australia  
 Edgar Mocanu, Rotunda Hospital, Ireland  
 Ben Mol, Monash University, Australia  
 Rachel Mormon, Verity—PCOS Charity, UK  
 Sharon Oberfield, Columbia University Medical Center, USA  
 Malika Patel, University of Cape Town; Groote Schuur Hospital, South Africa  
 Loyal Pattuwage, Cochrane Australia, Monash University, Australia  
 Alexia Peña, The Robinson Research Institute at the University of Adelaide, Australia  
 Leanne Redman, Pennington Biomedical Research Center, USA  
 Luk Rombauts, Monash University, Australia  
 Daniela Romualdi, Fondazione Policlinico Universitario Agostino Gemelli, Italy  
 Duru Shah, PCOS Society of India; Centre for Women's Health and Fertility, India  
 Poli Mara Spritzer, Federal University of Rio Grande Do Sul, Brazil  
 Elisabet Stener-Victorin, Karolinska Institutet, Sweden  
 Fahimeh Ramezani Tehrani, Shahid Beheshti University of Medical Sciences, Iran  
 Shakila Thangaratinam, University of Birmingham, UK  
 Mala Thondan, Harp Family Medical, Australia  
 Eszter Vanky, Norwegian University of Science and Technology; Norway  
 Chandrika Wijeyaratne, University of Colombo, Sri Lanka  
 Selma Witchel, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, USA  
 Dongzi Yang, Reproductive Medical Centre, Sun Yat-Sen Memorial Hospital, China  
 Bulent Yildiz, Hacettepe University, Turkey

### International Early Career Evidence Synthesis Network Leads

Simon Alesi, Monash University, Australia  
 Snigdha Alur-Gupta, University of Rochester, USA  
 Jodie Avery, University of Adelaide, Australia

Mahnaz Bahri Khomami, Monash University, Australia  
 Jamie Benham, University of Calgary, Canada  
 Hugh Bidstrup, Australian Catholic University, Australia  
 Su Jen Chua, Monash University, Australia  
 Laura Cooney, University of Wisconsin, USA  
 Thisara Coster, Monash University, Australia  
 Carolyn Ee, Western Sydney University, Australia  
 Victoria Fitz, Harvard University, USA  
 Madeline Flanagan, Monash University, Australia  
 Maria Forslund, University of Gothenburg, Sweden  
 Geranne Jiskoot, Erasmus MC, Netherlands  
 Maryam Kazemi, Icahn School of Medicine at Mount Sinai, USA  
 Punith Kempegowda, University of Birmingham, UK  
 Yvonne Louwers, Erasmus MC, Netherlands  
 Marla Lujan, Cornell University, USA  
 Johanna Melin, University of Helsinki, Finland  
 Eka Melson, University of Leicester, UK  
 Yitayeh Belsti Mengistu, Monash University, Australia  
 Negar Naderpoor, Monash University, Australia  
 Adriana Neven, Monash University, Australia  
 Hester Pastoor, Erasmus MC, Netherlands  
 Thais Rocha, University of Birmingham, UK  
 Angelo Sabag, Western Sydney University, Australia  
 Anuradha Subramanian, University of Birmingham, UK  
 Katrina Tan, Monash Health, Australia

### References

1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Med.* 2010;8(1):41.
2. Azziz R, Carmina E, Chen Z, *et al.* Polycystic ovary syndrome. *Nat Rev Dis Primers.* 2016;2(1):16057.
3. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and lack of information associated with dissatisfaction in women with polycystic ovary syndrome. *J Clin Endo & Metab.* 2017;102:604-612.
4. Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. *Fertil Steril.* 2017;107(6):1380-1386.e1.
5. Teede H, Gibson-Helm M, Norman RJ, Boyle J. Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome. *J Clin Endocrinol Metab.* 2014;99(1):E107-E111.
6. Teede J Helena, Marie Misso, Michael Costello, *et al.* International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018 [www.monash.edu/medicine/mchri/pcos](http://www.monash.edu/medicine/mchri/pcos)
7. Teede HJ, Misso ML, Costello MF, *et al.* Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod.* 2018;33(9):1602-1618.
8. Misso ML, Teede HJ. Evidence based guideline (EBG) development: A practical guide. In: Ilic D, ed. *Knowledge Transfer: Practices, Types and Challenges.* Nova Science Publishers, Inc.; 2012:141-174.
9. Brouwers MC, Kho ME, Browman GP, *et al.* AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ.* 2010;182(18):E839-E842.
10. Mousa A, Tay CT, Teede H. Technical Report for the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University. Report; 2023. <https://doi.org/10.26180/23625288.v1>

11. Weibel S, Popp M, Reis S, Skoetz N, Garner P, Sydenham E. Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis. *Res Synth Methods*. 2023;14(3):357-369.
12. Mol BW, Lai S, Rahim A, *et al*. Checklist to assess Trustworthiness in RAndomised Controlled Trials (TRACT checklist): concept proposal and pilot. *Res Integrity Peer Rev*. 2023;8(1):6.
13. National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of guidelines. Australia; 2009.
14. National Health and Medical Research Council. NHMRC standards and procedures for externally developed guidelines. Australia; 2007.
15. GRADE working group. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines.